Usted buscó: radjutikkettati (Maltés - Inglés)

mediċini oħra u mediċini radjutikkettati b’cuprymina
other medicines and medicines radiolabelled with cuprymina

il-mediċini radjutikkettati b’endolucinbeta jintużaw biss f’żoni kkontrollati u speċjali.
medicines radiolabelled with endolucinbeta will only be used in special controlled areas.

il-mediċini radjutikkettati b’cuprymina jintużaw biss f’żoni kkontrollati u spe ċjali.
medicines radiolabelled with cuprymina will only be used in special, controlled areas.

ytracis huwa maħsub biex jigu radjutikkettati prodotti mediëinali in vitro, li wara jigħataw bil- metodu approvat.
ytracis is intended for in vitro radiolabelling of medicinal products, which are subsequently administered by approved route.

ser tiġi mitluba tieqaf tredda’ jekk qiegħda tiġi kkurata b’mediċini radjutikkettati b’lumark.
you will be asked to stop breast-feeding if you are treated with medicines radiolabelled with lumark.

il-mediċini radjutikkettati b'lumark ma għandhomx jintużaw f'nisa tqal jew nisa li jistgħu jkunu tqal.
medicines radiolabeled with lumark must not be used in pregnant women or women who may be pregnant.

għandu jintuża biss biex jiġu radjutikkettati molekuli portaturi li ġew żviluppati speċifikament u ġew awtoriżżati biex jiġu radjutikkettati b' dan ir- radjunuklidu.
to be used only for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.

il-mediċini radjutikkettati b'endolucinbeta ma għandhomx jintużaw f'nisa tqal jew f'nisa li jistgħu jkunu tqal.
medicines radiolabelled with endolucinbeta must not be used in pregnant women or women who may be pregnant.

il- prodotti li ġejjin għandhom ikunu disponibbli f' istituzzjonijiet mediċi, li jużaw ytracis biex jiġu radjutikkettati molekoli portaturi għal skopijiet terapewtiċi:
the following preparations must be available in medical institutions, which use ytracis for radiolabelling of carrier molecules for therapeutic purposes:

minbarra hekk, ma nstabux metaboli fil- plażma wara li ngħataw mediċini radjutikkettati lill- bnedmin bbażati fuq l- ammont totali radjutikkettat u konċentrazzjonijiet mikrobijoloġikament attivi.
furthermore, no metabolites have been observed in plasma following administration of radiolabeled drug to humans based on total radiolabel and microbiologically active concentrations.

lumark jintuża biss biex jiġu radjutikkettati mediċini li ġew żviluppati speċifikament għall-użu mas-sustanza attiva klorur tal-lutezju (177lu).
lumark is only used to radiolabel medicines that have been specifically developed for use with the active substance lutetium (177lu)chloride.

il-metabolit prinċipali ta' voriconazole huwa l-ossidu n, li jammonta għal 72 % tal-metaboliti radjutikkettati li jiċċirkolaw fil-plasma.
the major metabolite of voriconazole is the n-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma.